ALOX15 and chronic kidney disease: A series of Alox15-derived PUFA metabolites such as 14-HDoHE, 17-HDoHE, and 15-HEPE [5, 25–27] was significantly increased in CKD models that correlated well to the increased level of ALOX15 expression in the kidneys (P = 0.0018, 0.0008, < 0.0001, respectively), and their elevations under CKD conditions were completely suppressed in Alox15−/− mice (Fig. 5).